Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.76 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089680 | 0.96 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4522796 | 0.87 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL9212451 | 0.86 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL31235656 | 0.86 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL7742536 | 0.84 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL7734745 | 0.82 | HDAC1 (0.90) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2242298 | 0.81 | SMN1; SMN2 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL5803935 | 0.81 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL7364115 | 0.80 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL31687530 | 0.80 | SIGMAR1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-7470794-B2 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | HDAC1 137/4885HDAC2 353/4885HDAC3 263/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HDAC1 2598/4885HDAC2 684/4885HDAC3 868/4885 |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | MMP1, MMP7, MMP2 | HDAC1 137/4885HDAC2 353/4885HDAC3 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.